Why the study?
Limited international research exists on coexisting NOAF and septic shock, making optimal antiarrhythmic management difficult to determine.
Does amiodarone improve outcomes compared to other antiarrhythmic drugs in patients with new-onset atrial fibrillation and septic shock?
Does amiodarone improve outcomes compared to other antiarrhythmic drugs in patients with new-onset atrial fibrillation and septic shock?
In patients with septic shock and new-onset atrial fibrillation, amiodarone may be preferred if underlying structural heart disease is present, while propafenone may be considered in its absence.
Amiodarone in septic shock with NOAF requires hemodynamic caution; leaves open safer alternatives in prospective trials.
Background and Objective: New-onset atrial fibrillation (NOAF) is a common cardiac condition often observed in intensive care units. When amiodarone is used to treat this condition, either to maintain sinus rhythm after electrical cardioversion or to control heart rate, complications can arise when a systemic pathology is present. Systemic pathology can result in a decrease in cardiac output and blood pressure, making the management of NOAF and septic shock challenging. Limited international research exists on the coexistence of NOAF and septic shock, making it difficult to determine the optimal course of treatment. While amiodarone is not the primary choice of antiarrhythmic drug for patients in septic shock, it may be considered for those with underlying cardiac issues. This paper aims to investigate the safety of administering amiodarone to patients with septic shock and explore whether another antiarrhythmic drug may be more effective, especially considering the cardiac conditions that patients may have. Materials and Methods: To write this article, we searched electronic databases for studies where authors used amiodarone and other medications for heart rate control or sinus rhythm restoration. Results: The studies reviewed in this work have shown that for the patients with septic shock and NOAF along with a pre-existing cardiac condition like a dilated left atrium, the use of amiodarone may provide greater benefits compared to other antiarrhythmic drugs. For patients with NOAF and septic shock without underlying heart disease, the initial use of propafenone has been found to be advantageous. However, a challenge arises when deciding between rhythm or heart rate control using various drug classes. Unfortunately, there is limited literature available on this specific scenario. Conclusions: NOAF is a frequent and potentially life-threatening complication occurring in one out of seven patients with sepsis, and its incidence is rising among patients with septic shock.
No takes yet. Share an insight, caveat, or question.
Oprea et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: